For the second quarter of 2026, analysts expect Oncolytics Biotech to report an EPS of -$0.06 on zero revenue, with the current $1.45 share price trading significantly below the $5.50 average analyst target.
The central focus for market participants is the management's update regarding the registration-enabling study for pelareorep in metastatic breast cancer.
Investors are also closely monitoring the company's cash position to ensure sufficient funding for the GOBLET and BRACELET-1 trial expansions. Any updates on potential strategic partnerships with major pharmaceutical firms could act as a significant catalyst for the stock.